EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Baseline Hemoglobin Predicts Oncologic Outcomes in Intrahepatic Cholangiocarcinoma Treated With Yttrium‐90 Radioembolisation: A Retrospective Cohort Study of 136 Patients

Saad Abu Zahra iD, Muhamad Serhal, Aakash N Gupta iD, Ahmed Gabr iD, Arsalan Nadeem, Ashima Kundu, Daniel Borja-Cacho, Aparna Kalyan, Laura M Kulik, Amir A Borhani, Robert J Lewandowski, Andrew C Gordon iD

Journal of Medical Imaging and Radiation Oncology · 2026-08 · 70 (5) · 447-456

DOI: 10.1111/1754-9485.70107 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Medical Imaging and Radiation Oncology, online erschienen am 26.04.2026. Verfasst von Saad Abu Zahra und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Yttrium Radioisotopes, Cholangiocarcinoma, Radioembolization, Therapeutic, Bile Duct Neoplasms. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Tumour oxygenation influences the radiobiological effect of yttrium‐90 (Y90); thus, baseline hemoglobin (HGB) may affect treatment response. This study evaluated whether baseline HGB is associated with outcomes in patients with unresectable intrahepatic cholangiocarcinoma (ICC) treated with Y90 transarterial radioembolisation (TARE).

Methods

We retrospectively analysed 136 ICC patients treated with glass microsphere Y90 from 2004 to 2020, stratified by baseline HGB: ≥ 12 g/dL, 10–11.9 g/dL, and < 10 g/dL. Kaplan–Meier and log‐rank tests assessed duration of response (DoR), overall survival (OS), and time to progression (TTP). Lesion response was evaluated by RECIST 1.1. Several clinical and radiologic parameters were evaluated in multivariate Cox models to identify independent OS predictors.

Results

Mean age was similar across HGB groups (~64 years, p = 0.934), and 49% of the cohort was female. Response rates differed significantly: For RECIST 1.1, responders comprised 38% (15/39) (≥ 12 g/dL), 42% (22/53) (10–11.9 g/dL), and 18% (7/39) (< 10 g/dL) ( p = 0.041). Median DoR was longest for HGB ≥ 12 g/dL (15.0 months) vs. 6.5 and 6.2 months for 10–11.9 and < 10 g/dL ( p = 0.041). TTP varied significantly (7.1, 5.8, and 1.7 months; p = 0.008). Median OS was 17.1, 13.8, and 6.0 months for ≥ 12, 10–11.9, and < 10 g/dL, respectively ( p < 0.001). On multivariate analysis, HGB < 10 g/dL remained independently associated with poorer OS (HR 1.83, p = 0.031).

Conclusion

Baseline HGB < 10 g/dL was a predictor of poor antitumor response, earlier progression, and worsened OS in ICC patients undergoing Y90 TARE. HGB is a low‐cost, clinically available biomarker that may aid in risk stratification and treatment planning. Future work should assess if risk factor modification prior to TARE (i.e., transfusion for HGB < 10) improves clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Yttrium RadioisotopesCholangiocarcinomaRadioembolization, TherapeuticBile Duct NeoplasmsHemoglobinsHumansFemaleRetrospective StudiesMaleMiddle AgedTreatment OutcomeAged

Stichwörter der Autor:innen

anemiaintrahepatic cholangiocarcinomaradioembolisationsurvivaltumour response

Substanzen

Yttrium RadioisotopesHemoglobinsYttrium-90

Autor:innen und Institutionen

  • Department of Radiology, Northwestern University, Chicago, Illinois, USA.
  • Section of Vascular and Interventional Radiology, Department of Radiology, Stanford University, California, USA.
  • Department of Surgery, Division of Transplant Surgery, Northwestern University, Chicago, Illinois, USA.
  • Department of Medical Social Sciences, Northwestern University, Chicago, Illinois, USA.
  • Department of Medicine, Division of Haematology and Oncology, Northwestern University, Chicago, Illinois, USA.
  • Department of Medicine, Division of Hepatology, Northwestern University, Chicago, Illinois, USA.

ORCID-Profile: Saad Abu Zahra, Aakash N Gupta, Ahmed Gabr, Andrew C Gordon

Zitieren

APA

Zahra, S. A., Serhal, M., Gupta, A. N., Gabr, A., Nadeem, A., Kundu, A., Borja-Cacho, D., Kalyan, A., Kulik, L. M., Borhani, A. A., Lewandowski, R. J., & Gordon, A. C. (2026). Baseline Hemoglobin Predicts Oncologic Outcomes in Intrahepatic Cholangiocarcinoma Treated With Yttrium‐90 Radioembolisation: A Retrospective Cohort Study of 136 Patients. Journal of Medical Imaging and Radiation Oncology, 70(5), 447-456. https://doi.org/10.1111/1754-9485.70107

Vancouver

Zahra SA, Serhal M, Gupta AN, Gabr A, Nadeem A, Kundu A, et al. Baseline Hemoglobin Predicts Oncologic Outcomes in Intrahepatic Cholangiocarcinoma Treated With Yttrium‐90 Radioembolisation: A Retrospective Cohort Study of 136 Patients. Journal of Medical Imaging and Radiation Oncology. 2026;70(5):447-456. doi:10.1111/1754-9485.70107

BibTeX
@article{Zahra2026,
  author = {Zahra, Saad Abu and Serhal, Muhamad and Gupta, Aakash N and Gabr, Ahmed and Nadeem, Arsalan and Kundu, Ashima and Borja-Cacho, Daniel and Kalyan, Aparna and Kulik, Laura M and Borhani, Amir A and Lewandowski, Robert J and Gordon, Andrew C},
  title = {Baseline Hemoglobin Predicts Oncologic Outcomes in Intrahepatic Cholangiocarcinoma Treated With Yttrium‐90 Radioembolisation: A Retrospective Cohort Study of 136 Patients},
  journal = {Journal of Medical Imaging and Radiation Oncology},
  year = {2026},
  volume = {70},
  number = {5},
  pages = {447--456},
  doi = {10.1111/1754-9485.70107}
}
Kostenlos starten →